Hepatitis C

Hepatitis C is a major worldwide viral disease and a systemic medical problem rather than an illness confined to the liver. Affecting an estimated 3% of the world population—around 170 million people in the cited global estimates—it produces chronic liver injury, fibrosis, cirrhosis, and hepatocellular carcinoma while also provoking autoimmune, dermatological, vascular, and renal disease. Its importance is especially pronounced in chronic kidney disease, hemodialysis, and kidney transplantation, where infection influences screening, transmission control, treatment decisions, glomerular pathology, and graft survival.

Definition and Global Burden

Hepatitis C infection is one of the principal causes of chronic liver disease worldwide. Prevalence varies sharply by region: estimates in Western Europe range from 0.4% to 3%, while prevalence is higher in Eastern Europe and the Middle East and reaches as high as 13% in Egypt. Many infected people remain unaware of their status. In the United States, the infected population was estimated to decline from 3.15 million in 2005 to 2.47 million in 2021 even as the burden increased with population aging; only about half of infections had been diagnosed and fewer than 4% had been treated.

The apparent decline in new infections has not removed the disease's public-health weight. In industrialized countries, new infections are concentrated mainly among people who inject drugs, although nasal drug use, unsafe medical or surgical procedures, and mother-to-child transmission remain relevant. Heterosexual transmission is generally low but is higher among HIV-infected men who have sex with men. Tattooing and acupuncture performed with unsafe materials can transmit infection, and roughly 30% of cases remain unexplained. Before the 1990s, transfusion of blood products and unsafe injections accounted for much of the transmission in industrialized countries; systematic blood screening reduced the residual transfusion risk to approximately one infection per two million donations.

The disease burden is also delayed. Models cited in the text projected that morbidity, mortality, and HCV-related costs would continue to rise, with hepatocellular carcinoma and HCV-related mortality increasing until about 2015. Progression is particularly concerning in people with metabolic syndrome, heavy alcohol intake, or other liver comorbidities, but serious hepatic injury may exist even when liver disease appears compensated.

Transmission, Genotypes, and Diagnosis

Six major HCV genotypes and numerous subtypes are described. Genotype 1 is the most prevalent worldwide: subtype 1b is common in Japan and Europe, while subtype 1a predominates in the United States. Genotype 2 forms clusters in the Mediterranean region, genotype 3a is frequent in the Indian subcontinent and among European intravenous drug users, genotype 4 is historically associated with Egypt and Africa but has increased among European intravenous drug users, genotype 5 is uncommon, and genotype 6 is found mainly in south China. These geographic patterns matter because genotype has historically influenced treatment choice and duration.

The diagnostic distinction between previous exposure and active disease is molecular as well as serological. Third-generation enzyme-linked immunosorbent assays detect anti-HCV antibodies, but antibody positivity alone cannot establish ongoing infection: it may represent either resolved or chronic disease. Active infection is demonstrated by detectable HCV RNA in serum through sensitive molecular assays, with a threshold of approximately 15 IU/ml. Chronic infection should therefore be established by the combination of anti-HCV positivity and HCV RNA positivity, including persistence for more than six months when chronicity is being defined.

Diagnosis also requires assessment of damage beyond the presence of virus. Active chronic infection calls for evaluation of both hepatic and extrahepatic effects, especially cryoglobulinemia-associated vasculitis. Liver biopsy can grade necroinflammation and stage fibrosis, but noninvasive methods such as biochemical scores and FibroScan liver-stiffness measurement can avoid approximately half of biopsies and permit yearly monitoring in untreated patients. Among people being evaluated for kidney transplantation, as many as 25% of those with active infection have advanced fibrosis on biopsy despite well-compensated disease, making systematic screening essential. In low-prevalence regions, screening begins with an enzyme immunoassay followed by nucleic acid testing for antibody-positive patients; in high-prevalence regions, nucleic acid testing should be used first because a negative antibody assay cannot reliably exclude infection.

Natural History and Treatment

Acute infection is frequently silent: asymptomatic forms account for approximately 50–90% of cases. About 10% of acute hepatitis cases in Europe are attributed to acute Hepatitis C, while the incidence has fallen to roughly one case per 100,000 people per year as blood screening, hygienic practice, and treatment have improved. Spontaneous resolution occurs in around 30% of acute cases, influenced by the route of transmission, symptomatic presentation, age at infection, immune status, and genetic variation near the lambda interferon gene. The IL28B CC genotype is associated with a higher probability of spontaneous clearance.

Treatment is recommended across the course of infection, with timing and duration guided by viral kinetics and genotype. If HCV RNA remains detectable about 12 weeks after acute infection, a 24-week course of pegylated interferon is indicated; treatment may be extended to 48 weeks when RNA remains detectable at week 4 or week 12. In chronic infection, therapy is considered according to disease impact, including chronic fatigue, necroinflammation, fibrosis beyond the earliest stage, or symptomatic extrahepatic disease such as cryoglobulinemia-associated vasculitis with renal, cutaneous, or neurological manifestations.

For much of the period covered by the text, the standard regimen combined once-weekly subcutaneous pegylated interferon with twice-daily oral ribavirin. According to early viral kinetics, this approach produced sustained virologic response in more than half of patients with chronic infection. Sustained virologic response represents virologic recovery and, in the absence of major liver comorbidity, permits inactivation of necroinflammation and remodeling of fibrosis. Genotype 1 remained more difficult to treat, with more than half of genotype 1-infected patients failing to achieve this endpoint under the older regimen.

The therapeutic landscape then shifted toward direct-acting antivirals directed at defined stages of the viral cycle. Protease NS3/4A inhibitors, polymerase NS5B inhibitors, broader-spectrum NS5A and entry inhibitors, cyclophilin inhibitors, new interferons, immune modulators, and therapeutic vaccines were under development. The first-generation protease inhibitors telaprevir and boceprevir increased sustained virologic response rates in genotype 1 infection by approximately 20–30%. About 75% of previously untreated genotype 1 patients achieved sustained response with telaprevir-based triple therapy, and about 65% achieved it with boceprevir-based therapy involving a four-week lead-in with the standard combination. In treatment-experienced patients, triple therapy produced responses of roughly 85% among previous relapsers, 55% among partial responders, and 30% among null responders. The gains came with costs and hazards, including rash, anemia, expense, adherence demands, viral resistance, and drug interactions.

Renal Disease and Systemic Manifestations

Hepatitis C is the major cause of mixed cryoglobulinemia, a systemic vasculitis that may produce arthralgias, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Cryoglobulins are essential to the diagnosis, and serum HCV RNA is usually present. Rheumatoid factor may be positive, while liver enzymes can be normal or only mildly elevated. Renal manifestations include proteinuria, hematuria, and reduced estimated glomerular filtration rate; acute nephritic syndrome occurs in about 25% of affected patients and nephrotic syndrome in about 20%. Purpura, arthralgia, or neuropathy may precede kidney disease by several years.

The infection is mainly associated with type II mixed cryoglobulinemia, and type I membranoproliferative glomerulonephritis—also called cryoglobulinemic glomerulonephritis—is the characteristic and most frequent renal lesion in this setting. More broadly, all patients described with Hepatitis C-associated glomerulonephritis were HCV RNA-positive in serum. The relationship is reflected epidemiologically: the prevalence of HCV seropositivity among patients with membranoproliferative glomerulonephritis was reported to be about ten times that observed among HCV-negative patients.

Hepatitis C is also associated with a higher risk of chronic kidney disease outside overt cryoglobulinemic disease. In a United States study of 18,002 infected people and 25,137 controls with baseline estimated glomerular filtration rate above 60, infection was associated with a greater risk of developing stage 3–5 chronic kidney disease. Older age, hypertension, diabetes, and decompensated liver disease increased risk in both groups, but infected patients reached chronic kidney disease sooner. In another comparison, chronic kidney disease affected 9.6% of anti-HCV-positive patients versus 5.1% of HCV-negative patients, and higher baseline viral load independently predicted kidney disease. Survey data further found age-dependent associations with albuminuria: among people aged 60 or older, albuminuria was present in 46% of HCV-positive individuals compared with 24% of antibody-negative individuals. A Taiwanese analysis similarly found proteinuria in 8.3% of anti-HCV-positive non-diabetic patients versus 5.1% of seronegative patients.

Hemodialysis, Infection Control, and Transplantation

Hemodialysis patients became recognized as a high-risk group soon after serological tests became available. In the early 1990s, prevalence and incidence were high in western countries. Transfusion initially contributed substantially because patients receiving hemodialysis often required blood products, but the transfusion risk fell from approximately 0.5% per blood unit in the 1980s to around 0.0001%, or one case per million blood units, in the United States. Attention therefore shifted toward nosocomial transmission within dialysis units. Prevalence correlated with time on dialysis, exceeded that among peritoneal dialysis and home-hemodialysis patients, and remained substantial in some never-transfused patients.

Molecular virology made the institutional transmission problem visible. From the mid-1990s onward, phylogenetic analyses identified clusters of closely related HCV isolates among patients treated in the same hemodialysis unit. Variable genomic regions allowed investigators to fingerprint viral isolates or quasi-species and estimate the probability that infections came from a common source. A KDIGO review of 20 such studies found that no individual route could be conclusively established after the event, but every study implicated failures in infection-control procedures. In 18 of the 20 studies, some or all newly infected patients had not shared a dialysis machine with the presumed source patient, weakening the case for the machine's internal fluid pathway as the usual mechanism.

The resulting prevention strategy emphasizes rigorous hygiene rather than routine segregation. Dedicated machines for infected patients were not recommended because the reviewed evidence did not show that they were necessary. Separate-ward isolation likewise showed no protective effect after adjustment for confounding in large prospective observational studies, including the Dialysis Outcomes and Practice Patterns Study and an Italian study, and was not recommended as a substitute for strict infection control. Staff should wash or antiseptically clean their hands before and after contact with patients or equipment, use disposable gloves at the dialysis station, remove gloves before leaving it, discard single-use materials after one patient, disinfect nondisposable equipment and contaminated surfaces, manage waste appropriately, and undergo regular observational audits. Even where dialyzer reuse is unavoidable, reuse for HCV-infected patients can be considered only with strict adherence to infection-control procedures.

The infection also complicates kidney transplantation. Before transplantation, chronic infection has been reported in approximately 7–40% of kidney recipients, with variation by geography and demographics. Longer duration of end-stage renal disease, previous transplantation, Black race, hepatitis B coinfection, prior substance abuse, and diabetes are associated with infection in this population. Diabetes affects about 30% of infected kidney candidates aged 30–50 and rises to 63% among elderly candidates, adding to their comorbidity burden.

After transplantation, Hepatitis C is a major independent risk factor for renal allograft loss and remains predictive even in protocol-biopsy studies. Some of the adverse effect may reflect the population's heightened immunological risk, including retransplantation, prolonged renal disease, and stronger cellular and humoral immune responses. Infection has been associated with glomerulitis and transplant glomerulopathy, lesions linked to anti-HLA antibodies and antibody-mediated rejection. It is also associated with post-transplant proteinuria, thrombotic microangiopathy in the presence of pretransplant anticardiolipin antibodies, and immune complex-mediated glomerulonephritis in renal and liver allografts.

De novo membranoproliferative glomerulonephritis has been described in HCV-infected renal allograft recipients, later linked to type II mixed cryoglobulinemia with IgM-kappa monoclonal components. Unlike nontransplanted patients, these recipients often have very low cryocrit levels, usually below 5%, which can make cryoglobulins difficult to detect and characterize; HCV RNA may nevertheless be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for the virus. Clinical features include hypertension, microhematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy may show mesangial proliferation, double contours, and parietal IgM and C3 deposits. Electron microscopy can distinguish membranoproliferative glomerulonephritis, with subendothelial electron-dense deposits, from transplant glomerulopathy, which shows radiolucent areas in the glomerular basement membrane; both lesions can coexist. Hepatitis C-associated membranous glomerulonephritis has also been reported in renal allografts, usually with nephrotic syndrome, although a clear pathogenic connection is often absent because cryoglobulins, immune complexes, and complement activation are generally not found.

Significance in Medical Knowledge and Practice

The history of Hepatitis C is a history of increasingly precise medical classification. The disease moved from the category of non-A, non-B hepatitis toward a defined viral infection, then toward a molecularly stratified condition identified through antibody testing, RNA detection, viral genotyping, and genomic comparison. This progression changed both the object being diagnosed and the actions attached to it: antibody positivity became insufficient without RNA confirmation, fibrosis could be followed without repeated biopsy, and treatment could be tailored to genotype and viral kinetics.

The same expansion transformed Hepatitis C from a liver-centered diagnosis into a coordinated field spanning nephrology, dialysis, transplantation, immunology, and infection control. KDIGO treated it as a major nephrology topic because the virus could cause chronic kidney disease, mixed cryoglobulinemia, membranoproliferative glomerulonephritis, dialysis-unit transmission, and poor renal-allograft outcomes. Blood screening reduced one historical route of infection, molecular epidemiology exposed another, and infection-control practice redirected prevention away from assumptions about dedicated machines or isolation and toward the repeated discipline of hand hygiene, gloves, equipment disinfection, waste management, and auditing.

Therapeutic progress further altered the disease's trajectory. Pegylated interferon and ribavirin offered viral eradication for many patients but left genotype 1 inadequately served and imposed substantial treatment burdens. Direct-acting antiviral combinations targeted the viral cycle more directly and raised response rates, while also introducing new concerns about resistance, interactions, safety, cost, and adherence. Hepatitis C therefore stands simultaneously as a biological infection, a measurable population risk, a source of extrahepatic disease, and a test of how medical institutions convert evolving molecular knowledge into screening, treatment, prevention, and transplant policy.